Savara Inc. (SVRA) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Savara Inc. (SVRA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.81

0.09 (3.31%)

At close: Jan 15, 2025, 11:15 AM

undefined% (undefined)

Bid	2.8
Market Cap	482.25M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.43
PE Ratio (ttm)	-6.53
Forward PE	n/a
Analyst	Buy

Ask	2.81
Volume	300,311
Avg. Volume (20D)	1,445,873
Open	2.80
Previous Close	2.72
Day's Range	2.77 - 2.85
52-Week Range	2.60 - 5.70
Beta	undefined

About SVRA

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas....

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 28, 2017

Employees 37

Stock Exchange NASDAQ

Ticker Symbol SVRA

Website https://www.savarapharma.com

Analyst Forecast

According to 7 analyst ratings, the average rating for SVRA stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 220.28% from the latest price.

Buy 85.71%

Hold 14.29%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 months ago · Source

-15.14%

Savara shares are trading lower after Evercore ISI... Unlock content with Pro Subscription

6 months ago · Source

+1.05%

Savara shares are trading lower, pulling back after initially rising on Phase 3 IMPALA-2 clinical trial results.

News

3 weeks ago · businesswire.com

Savara Announces New Employment Inducement Grant

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new...

4 weeks ago · businesswire.com

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, initiated a rolling submission of a BLA to t...

4 weeks ago · businesswire.com

Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company will presen...

1 month ago · businesswire.com

Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024

2 months ago · businesswire.com

Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that a new episode of The Balancin...